Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
96,816,883
-
Shares change
-
-2,147,169
-
Total reported value, excl. options
-
$218,731,670
-
Value change
-
-$6,193,557
-
Put/Call ratio
-
13%
-
Number of buys
-
65
-
Number of sells
-
-50
-
Price
-
$2.26
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2021
154 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2021.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 96,816,883 shares
of 236,234,693 outstanding shares and own 40.98% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14,124,215 shares), VANGUARD GROUP INC (13,235,669 shares), STATE STREET CORP (11,743,461 shares), Nantahala Capital Management, LLC (4,918,565 shares), SATTER MANAGEMENT CO., L.P. (4,652,561 shares), MARSHALL WACE, LLP (4,475,138 shares), JPMORGAN CHASE & CO (4,432,016 shares), GEODE CAPITAL MANAGEMENT, LLC (3,207,989 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2,737,900 shares), and DIMENSIONAL FUND ADVISORS LP (2,593,841 shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.